Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Shuart, Noah Gregory"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Hebbar, Malavika, Al-Taweel, Nawaf, Gill, Inderpal, Boelman, Cyrus, Dean, Richard A., Goodchild, Samuel J., Mezeyova, Janette, Shuart, Noah Gregory, Johnson Jr., J. P., Lee, James, Michoulas, Aspasia, Huh, Linda L., Armstrong, Linlea, Connolly, Mary B., Demos, Michelle K.
Publikováno v:
BMC Neurology; 1/17/2024, Vol. 24 Issue 1, p1-7, 7p
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ghovanlooa, Mohammad-Reza1,2, Shuart, Noah Gregory2, Mezeyova, Janette2, Dean, Richard A.2, Ruben, Peter C.1, Goodchild, Samuel J.1,2 sgoodchild@xenonpharma.com
Publikováno v:
Journal of Biological Chemistry. 10/26/2018, Vol. 293 Issue 43, p16546-16558. 13p.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Johnson JP Jr; Department of In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Focken T; Department of Chemistry, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Karimi Tari P; Department of In Vivo Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Dube C; Department of In Vivo Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Goodchild SJ; Department of In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Andrez JC; Department of Chemistry, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Bankar G; Department of In Vivo Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Burford K; Department of Chemistry, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Chang E; Department of In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Chowdhury S; Department of Chemistry, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Christabel J; Department of In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Dean R; Department of In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., de Boer G; Department of Compound Properties, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Dehnhardt C; Department of Chemistry, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Gong W; Department of Chemistry, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Grimwood M; Department of Chemistry, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Hussainkhel A; Department of In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Jia Q; Department of Chemistry, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Khakh K; Department of In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Lee S; Department of Compound Properties, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Li J; Department of In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Lin S; Department of In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Lindgren A; Department of Compound Properties, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Lofstrand V; Department of Chemistry, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Mezeyova J; Department of In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Nelkenbrecher K; Department of In Vivo Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Shuart NG; Department of In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Sojo L; Department of Compound Properties, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Sun S; Department of Chemistry, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Waldbrook M; Department of In Vivo Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Wesolowski S; Department of Chemistry, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Wilson M; Department of Chemistry, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Xie Z; Department of In Vitro Biology, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Zenova A; Department of Chemistry, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Zhang W; Department of Chemistry, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Scott FL; Neurocrine Biosciences, San Diego, California, USA., Cutts AJ; Scientific Affairs, Xenon Pharmaceuticals, Inc, Burnaby, British Columbia, Canada., Sherrington RP; Executive Team, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Winquist R; Executive Team, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Cohen CJ; Executive Team, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada., Empfield JR; Executive Team, Xenon Pharmaceuticals Inc, Burnaby, British Columbia, Canada.
Publikováno v:
British journal of pharmacology [Br J Pharmacol] 2024 Jun 24. Date of Electronic Publication: 2024 Jun 24.
Autor:
Goodchild SJ; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals, Burnaby, BC V5G 4W8, Canada., Shuart NG; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals, Burnaby, BC V5G 4W8, Canada., Williams AD; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals, Burnaby, BC V5G 4W8, Canada., Ye W; Neurocrine Biosciences, San Diego, California 92130, United States., Parrish RR; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals, Burnaby, BC V5G 4W8, Canada., Soriano M; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals, Burnaby, BC V5G 4W8, Canada., Thouta S; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals, Burnaby, BC V5G 4W8, Canada., Mezeyova J; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals, Burnaby, BC V5G 4W8, Canada., Waldbrook M; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals, Burnaby, BC V5G 4W8, Canada., Dean R; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals, Burnaby, BC V5G 4W8, Canada., Focken T; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals, Burnaby, BC V5G 4W8, Canada., Ghovanloo MR; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals, Burnaby, BC V5G 4W8, Canada.; Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC V5A 1S6, Canada.; Department of Neurology, Yale University, New Haven, Connecticut 06519, United States., Ruben PC; Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC V5A 1S6, Canada., Scott F; Neurocrine Biosciences, San Diego, California 92130, United States., Cohen CJ; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals, Burnaby, BC V5G 4W8, Canada., Empfield J; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals, Burnaby, BC V5G 4W8, Canada., Johnson JP; Department of Cellular and Molecular Biology, Xenon Pharmaceuticals, Burnaby, BC V5G 4W8, Canada.
Publikováno v:
ACS chemical neuroscience [ACS Chem Neurosci] 2024 Mar 20; Vol. 15 (6), pp. 1169-1184. Date of Electronic Publication: 2024 Feb 15.